Anti-inflammatory and antioxidant properties of a new arylidene- thiazolidinedione in macrophages

Current Medicinal Chemistry

Volumn 18, Issue 22, 2011, Pages 3351-3360

  Faine, L A ^a   Rudnicki, M ^a   Cesar F A ^a   Heras, B L ^b   Bosca L ^c   Souza, E S ^d   Hernandes, M Z ^d   Galdino, S L ^d   Lima, M C A ^d   Pitta, I R ^d   Abdalla, D S P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Anti inflammatory; Diabetes; Macrophages; MitoNEET; NADPH oxidase; Nrf2; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (4 METHANESULFONYLBENZYLIDENE) 3 (4 NITROBENZYL)THIAZOLIDINE 2,4 DIONE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CD36 ANTIGEN; CYCLOOXYGENASE 2; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR SUBSTRATE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; ROSIGLITAZONE; SF 23; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BINDING AFFINITY; CELL PROTECTION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; MACROPHAGE; MACROPHAGE ACTIVATION; MITOCHONDRIAL MEMBRANE HYPERPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; THIAZOLIDINEDIONES;

EID: 79961075382     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796504600     Document Type: Conference Paper

References (38)

1. Nesto, R. W.; Bell, D.; Bonow, R. O.; Fonseca, V.; Grundy, S. M.; Horton, E. S.; Le, W. M.; Porte, D.; Semenkovich, C. F.; Smith, S.; Young, L. H.; Kahn, R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation, 2003, 108, 2941-2948.
2. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J.Biol.Chem., 1995, 270, 12953-12956.
3. Lehrke, M.; Lazar, M. A. The many faces of PPARgamma. Cell, 2005, 123, 993-999.
4. Alleva, D. G.; Johnson, E. B.; Lio, F. M.; Boehme, S. A.; Conlon, P. J.; Crowe, P. D. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor- gamma: counter-regulatory activity by IFN-gamma. J.Leukoc.Biol., 2002, 71, 677-685.
5. Fan, Y.; Wang, Y.; Tang, Z.; Zhang, H.; Qin, X.; Zhu, Y.; Guan, Y.; Wang, X.; Staels, B.; Chien, S.; Wang, N. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler. Thromb.Vasc.Biol., 2008, 28, 315-321. (Pubitemid 351161205)
6. Forst, T.; Karagiannis, E.; Lubben, G.; Hohberg, C.; Schondorf, T.; Dikta, G.; Drexler, M.; Morcos, M.; Danschel, W.; Borchert, M.; Pfutzner, A. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis, 2008, 197, 311-317. (Pubitemid 351273253)
7. Hanefeld, M.; Marx, N.; Pfutzner, A.; Baurecht, W.; Lubben, G.; Karagiannis, E.; Stier, U.; Forst, T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J.Am.Coll.Cardiol., 2007, 49, 290-297. (Pubitemid 46110954)
8. Jiang, C.; Ting, A. T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-86. (Pubitemid 28079219)
9. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82. (Pubitemid 28079218)
10. Haffner, S. M.; Greenberg, A. S.; Weston, W. M.; Chen, H.; Williams, K.; Freed, M. I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002, 106, 679-684. (Pubitemid 34851926)
11. Guan, Y.; Hao, C.; Cha, D. R.; Rao, R.; Lu, W.; Kohan, D. E.; Magnuson, M. A.; Redha, R.; Zhang, Y.; Breyer, M. D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat.Med., 2005, 11, 861-866. (Pubitemid 41161118)
12. Fonseca, V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am.J.Med., 2003, 115 Suppl 8A, 42S-48S.
13. Fukui, Y.; Masui, S.; Osada, S.; Umesono, K.; Motojima, K. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes, 2000, 49, 759-767. (Pubitemid 30339991)
14. Zhang, F.; Lavan, B. E.; Gregoire, F. M. Selective Modulators of PPARgamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR.Res., 2007, 2007, 32696.
15. Nicoletti, I.; Migliorati, G.; Pagliacci, M. C.; Grignani, F.; Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J.Immunol.Methods, 1991, 139, 271-279.
16. Floryk, D.; Houstek, J. Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Biosci.Rep., 1999, 19, 27-34. (Pubitemid 29248702)
17. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J.Am.Chem.Soc., 1985, 107, 3902-3909.
18. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J.Med.Chem., 2003, 46, 499-511. (Pubitemid 36182752)
19. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J. C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys.Acta, 2007, 1771, 1065-1081. (Pubitemid 47208546)
20. Chandalia, A.; Clarke, H. J.; Clemens, L. E.; Pandey, B.; Vicena, V.; Lee, P.; Lavan, B. E.; Gregoire, F. M. MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-gamma Agonist Lowers Triglyceride Independently of PPAR-alpha Activation. PPAR.Res., 2009, 2009, 706852.
21. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ.Res., 2010, 107, 1058-1070.
22. Collins, A. R.; Lyon, C. J.; Xia, X.; Liu, J. Z.; Tangirala, R. K.; Yin, F.; Boyadjian, R.; Bikineyeva, A.; Pratico, D.; Harrison, D. G.; Hsueh, W. A. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ.Res., 2009, 104, e42-e54.
23. Mersmann, J.; Tran, N.; Zacharowski, P. A.; Grotemeyer, D.; Zacharowski, K. Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock, 2008, 30, 64-68.
24. Ferguson, H. E.; Thatcher, T. H.; Olsen, K. C.; Garcia-Bates, T. M.; Baglole, C. J.; Kottmann, R. M.; Strong, E. R.; Phipps, R. P.; Sime, P. J. Peroxisome proliferator-activated receptor-gamma ligands induce heme oxygenase-1 in lung fibroblasts by a PPARgamma-independent, glutathione-dependent mechanism. Am.J.Physiol Lung Cell Mol.Physiol, 2009, 297, L912-L919.
25. Kronke, G.; Kadl, A.; Ikonomu, E.; Bluml, S.; Furnkranz, A.; Sarembock, I. J.; Bochkov, V. N.; Exner, M.; Binder, B. R.; Leitinger, N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator- activated receptors. Arterioscler.Thromb.Vasc.Biol., 2007, 27, 1276-1282. (Pubitemid 46809415)
26. Wayman, N. S.; Hattori, Y.; McDonald, M. C.; Mota-Filipe, H.; Cuzzocrea, S.; Pisano, B.; Chatterjee, P. K.; Thiemermann, C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J., 2002, 16, 1027-1040. (Pubitemid 34753509)
27. Lassegue, B.; Griendling, K. K. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler.Thromb.Vasc.Biol., 2010, 30, 653-661.
28. Bedard, K.; Krause, K. H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev., 2007, 87, 245-313. (Pubitemid 46209993)
29. Potenza, M. A.; Gagliardi, S.; De, B. L.; Zigrino, A.; Tiravanti, E.; Colantuono, G.; Federici, A.; Lorusso, L.; Benagiano, V.; Quon, M. J.; Montagnani, M. Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am.J.Physiol Endocrinol.Metab, 2009, 297, E685-E694.
30. Hwang, J.; Kleinhenz, D. J.; Lassegue, B.; Griendling, K. K.; Dikalov, S.; Hart, C. M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am.J.Physiol Cell Physiol, 2005, 288, C899-C905. (Pubitemid 40395068)
31. Colca, J. R.; McDonald, W. G.; Waldon, D. J.; Leone, J. W.; Lull, J. M.; Bannow, C. A.; Lund, E. T.; Mathews, W. R. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am.J.Physiol Endocrinol.Metab, 2004, 286, E252-E260. (Pubitemid 38140317)
32. Chawla, A.; Barak, Y.; Nagy, L.; Liao, D.; Tontonoz, P.; Evans, R. M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat.Med., 2001, 7, 48-52. (Pubitemid 32095641)
33. Marx, N.; Kehrle, B.; Kohlhammer, K.; Grub, M.; Koenig, W.; Hombach, V.; Libby, P.; Plutzky, J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantationassociated arteriosclerosis. Circ.Res., 2002, 90, 703-710. (Pubitemid 34640890)
34. Joseph, S. B.; Castrillo, A.; Laffitte, B. A.; Mangelsdorf, D. J.; Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat.Med., 2003, 9, 213-219. (Pubitemid 36227724)
35. Fujimoto, M.; Shimizu, N.; Kunii, K.; Martyn, J. A.; Ueki, K.; Kaneki, M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes, 2005, 54, 1340-1348. (Pubitemid 40586662)
36. Al-Khalili, L.; Forsgren, M.; Kannisto, K.; Zierath, J. R.; Lonnqvist, F.; Krook, A. Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma coactivator 1. Diabetologia, 2005, 48, 1173-1179. (Pubitemid 40909654)
37. Liao, W.; Nguyen, M. T.; Yoshizaki, T.; Favelyukis, S.; Patsouris, D.; Imamura, T.; Verma, I. M.; Olefsky, J. M. Suppression of PPAR-gamma attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. Am.J.Physiol Endocrinol.Metab, 2007, 293, E219- 227. (Pubitemid 47105935)
38. Hammarstedt, A.; Smith, U. Thiazolidinediones (PPARgamma ligands) increase IRS-1, UCP-2 and C/EBPalpha expression, but not transdifferentiation, in L6 muscle cells. Diabetologia, 2003, 46, 48-52. (Pubitemid 36237746)